Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03785405 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT03785405 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 216 participants.
The verdict
NCT03785405, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate long-term safety and tolerability and to provide post-trial access to sacubitril/valsartan to eligible participants who successfully completed CLCZ696B2319 (PANORAMA-HF) core study Part 2 as per protocol.
Interventions
- DRUG sacubitril/valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2023-12-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03785405
The ClinicalTrials.gov registry entry for NCT03785405 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sacubitril/valsartan is the first listed.
NCT03785405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03785405 about?
NCT03785405 is a clinical study titled "Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF". The purpose of this study was to evaluate long-term safety and tolerability and to provide post-trial access to sacubitril/valsartan to eligible participants who successfully completed CLCZ696B2319 (PANORAMA-HF) core study Part 2 as per protocol.
What is the current status of trial NCT03785405?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2019-05-02. Estimated completion is 2023-12-29.
What interventions are being tested in trial NCT03785405?
The interventions under investigation include: sacubitril/valsartan (DRUG).
Who is sponsoring clinical trial NCT03785405?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.